These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38253342)

  • 1. Lipoprotein(a) and cardiovascular disease: sifting the evidence to guide future research.
    Kamstrup PR; Neely RDG; Nissen S; Landmesser U; Haghikia A; Costa-Scharplatz M; Abbas C; Nordestgaard BG
    Eur J Prev Cardiol; 2024 May; 31(7):903-914. PubMed ID: 38253342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert position statements: comparison of recommendations for the care of adults and youth with elevated lipoprotein(a).
    Wilson DP; Koschinsky ML; Moriarty PM
    Curr Opin Endocrinol Diabetes Obes; 2021 Apr; 28(2):159-173. PubMed ID: 33534258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations.
    Shah NP; Pajidipati NJ; McGarrah RW; Navar AM; Vemulapalli S; Blazing MA; Shah SH; Hernandez AF; Patel MR
    Am J Cardiol; 2020 Jul; 126():94-102. PubMed ID: 32336532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and future role of lipoprotein(a) in preventive cardiology.
    Berman AN; Blankstein R
    Curr Opin Cardiol; 2019 Sep; 34(5):514-518. PubMed ID: 31261178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. All we need to know about lipoprotein(a).
    Bess C; Mehta A; Joshi PH
    Prog Cardiovasc Dis; 2024; 84():27-33. PubMed ID: 38759878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
    Boffa MB
    Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
    Vasquez N; Joshi PH
    Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.
    Guddeti RR; Patil S; Ahmed A; Sharma A; Aboeata A; Lavie CJ; Alla VM
    Prog Cardiovasc Dis; 2020; 63(4):496-502. PubMed ID: 32526213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Reyes-Soffer G; Ginsberg HN; Berglund L; Duell PB; Heffron SP; Kamstrup PR; Lloyd-Jones DM; Marcovina SM; Yeang C; Koschinsky ML;
    Arterioscler Thromb Vasc Biol; 2022 Jan; 42(1):e48-e60. PubMed ID: 34647487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
    Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
    Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective.
    Arsenault BJ; Kamstrup PR
    Atherosclerosis; 2022 May; 349():7-16. PubMed ID: 35606078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
    Tsimikas S; Fazio S; Ferdinand KC; Ginsberg HN; Koschinsky ML; Marcovina SM; Moriarty PM; Rader DJ; Remaley AT; Reyes-Soffer G; Santos RD; Thanassoulis G; Witztum JL; Danthi S; Olive M; Liu L
    J Am Coll Cardiol; 2018 Jan; 71(2):177-192. PubMed ID: 29325642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study of lipoprotein(a) and its impact on atherosclerotic cardiovascular disease: Design and rationale of the Mass General Brigham Lp(a) Registry.
    Berman AN; Biery DW; Ginder C; Hulme OL; Marcusa D; Leiva O; Wu WY; Singh A; Divakaran S; Hainer J; Turchin A; Januzzi JL; Natarajan P; Cannon CP; Di Carli MF; Bhatt DL; Blankstein R
    Clin Cardiol; 2020 Nov; 43(11):1209-1215. PubMed ID: 32893370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. To test, or not to test: that is the question for the future of lipoprotein(a).
    Ellis KL; Chakraborty A; Moses EK; Watts GF
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):241-250. PubMed ID: 30916582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
    Klingel R; Heibges A; Fassbender C;
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein(a) and cardiovascular disease: current state and future directions for an enigmatic lipoprotein.
    Saeed A; Virani SS
    Front Biosci (Landmark Ed); 2018 Jan; 23(6):1099-1112. PubMed ID: 28930591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.
    Wilson DP; Jacobson TA; Jones PH; Koschinsky ML; McNeal CJ; Nordestgaard BG; Orringer CE
    J Clin Lipidol; 2019; 13(3):374-392. PubMed ID: 31147269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipoprotein(a) and Cardiovascular Disease: A Missing Link for Premature Atherosclerotic Heart Disease and/or Residual Risk.
    Melita H; Manolis AA; Manolis TA; Manolis AS
    J Cardiovasc Pharmacol; 2022 Jan; 79(1):e18-e35. PubMed ID: 34694242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.